ANCA-associated vasculitis
The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a
group of disorders involving severe, systemic, small-vessel vasculitis and are characterized …
group of disorders involving severe, systemic, small-vessel vasculitis and are characterized …
B cells, antibodies, and more
W Hoffman, FG Lakkis, G Chalasani - Clinical Journal of the …, 2016 - journals.lww.com
B cells play a central role in the immunopathogenesis of glomerulonephritides and
transplant rejection. B cells secrete antibodies that contribute to tissue injury via multiple …
transplant rejection. B cells secrete antibodies that contribute to tissue injury via multiple …
ANCA glomerulonephritis and vasculitis
JC Jennette, PH Nachman - … Journal of the American Society of …, 2017 - journals.lww.com
ANCA vasculitis has an associated autoimmune response that produces ANCAs that induce
distinct pathologic lesions. Pauci-immune necrotizing and crescentic GN is a frequent …
distinct pathologic lesions. Pauci-immune necrotizing and crescentic GN is a frequent …
ANCA-associated vasculitis: an update
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group
of small vessel vasculitides characterized by granulomatous and neutrophilic tissue …
of small vessel vasculitides characterized by granulomatous and neutrophilic tissue …
Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease
JC Jennette, RJ Falk - Nature Reviews Rheumatology, 2014 - nature.com
Antineutrophil cytoplasmic autoantibodies (ANCAs) are the probable cause of a distinct form
of vasculitis that can be accompanied by necrotizing granulomatosis. Clinical and …
of vasculitis that can be accompanied by necrotizing granulomatosis. Clinical and …
Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology
Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare multisystemic disease
classified both amongst hypereosinophilic disorders and ANCA-associated vasculitis …
classified both amongst hypereosinophilic disorders and ANCA-associated vasculitis …
Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis
SP McAdoo, N Medjeral-Thomas… - Nephrology Dialysis …, 2019 - academic.oup.com
Background Current guidelines advise that rituximab or cyclophosphamide should be used
for the treatment of organ-threatening disease in anti-neutrophil cytoplasm antibody (ANCA) …
for the treatment of organ-threatening disease in anti-neutrophil cytoplasm antibody (ANCA) …
Effector and regulatory B cells in immune-mediated kidney disease
K Oleinika, C Mauri, AD Salama - Nature Reviews Nephrology, 2019 - nature.com
B cells have a central role in many autoimmune diseases, including in those with renal
involvement, as well as in the immunological response to kidney transplantation. The …
involvement, as well as in the immunological response to kidney transplantation. The …
Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis
F Alberici, RM Smith, RB Jones, DM Roberts… - …, 2015 - academic.oup.com
Objective. ANCA-associated vasculitis (AAV) is characterized by a chronic relapsing course.
Rituximab (RTX) is an effective maintenance treatment; however, the long-term outcomes …
Rituximab (RTX) is an effective maintenance treatment; however, the long-term outcomes …
Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis
WF Pendergraft III, FB Cortazar, J Wenger… - Clinical Journal of the …, 2014 - journals.lww.com
Results In the study, 172 patients (mean age= 60 years, 55% women, 57% myeloperoxidase–
ANCA) treated from April of 2006 to March of 2013 underwent continuous B-cell depletion …
ANCA) treated from April of 2006 to March of 2013 underwent continuous B-cell depletion …